Carotid Artery Disease, Stroke Prevention
Conditions
Keywords
carotid artery stenting, cerebral protection, stroke, ischemic lesion, DW-MRI
Brief summary
The purpose of this study is to detect new ischemic lesions after carotid artery stenting (with the Cristallo Ideale stent), in patients with high grade carotid artery stenosis, by diffusion-weighted magnetic resonance imaging (DW-MRI), using the endovascular proximal flow blockage (Mo.Ma device) for cerebral protection.
Interventions
DEVICECarotid artery stenting
The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure. For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal).
Sponsors
Invatec S.p.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥ 18 years old; 2. Eligibility for carotid artery revascularization; 3. A significant stenosis in symptomatic patients with ≥ 50% Diameter Stenosis (%DS) or asymptomatic ≥ 80 %DS as defined by angiography. Symptomatic is defined as a carotid artery stenosis associated with ipsilateral TIA, amaurosis fugax, ischemic stroke or retinal infarction within 6 months prior to enrollment. 4. Suitable clinical conditions to perform DW-MRI. 5. Written informed consent as approved by the Ethics Committee of the respective clinical site.
Exclusion criteria
1. Female with childbearing potential without a negative pregnancy test. 2. Life-expectancy less than 6 months. 3. Underlying disease of the carotid artery other than atherosclerosis (e.g. vasculitis, traumatic dissection, fibromuscular dysplasia). 4. Prior stenting in the target vessel; 5. Patients with chronic or re-current atrial fibrillation. 6. Patient has had a Myocardial Infarction within 72 hours prior to the procedure. 7. Patient experienced a stroke within 4 weeks prior to the procedure. 8. History of severe disabling stroke according to the modified Rankin scale \> 4. 9. Severe renal failure (serum creatinine \> 2.0 mg/dL). 10. Severe peripheral arterial occlusive disease, which might impede a safe introduction of a 9F-sheath for the use of a Mo.Ma-device. 11. Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Statins, Heparin, Nitinol, contrast agents (that cannot be adequately pre-medicated). 12. Patient currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the DESERVE study endpoints. 13. Any planned major surgery within 30 days after the study procedure. 14. In the investigators opinion patient has a severe co-morbid condition(s) that could limit the ability to participate in the study. Angiographic
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The de-novo occurrence of intra-cerebral lesions per patient by comparing baseline (within 1 week prior procedure) and post-procedural DW-MRI (from 3 to 12 hours post procedure). | 3-12 hours after index procedure |
Secondary
| Measure | Time frame |
|---|---|
| Device Success; Technical Success; Procedural Success; Restenosis rate at 30 days follow up; TLR at 30 days follow up; Access Site Complications; MACCE at 30 days; Incidence of TIA up to 30 days. | 30 days |
Countries
Germany, Italy, Poland
Outcome results
None listed